Inventor
David Frendewey
Inventor
New York, NY, US
Overview
Patents· 43 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C12Nprimary
C12NMicroorganisms or enzymes36%
A01KAnimal husbandry34%
C07KPeptides9%
C12YEnzymes9%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms7%
A61DVeterinary instruments, implements, tools, or methods3%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations1%
G01NInvestigating or analysing materials by determining their chemical or physical properties1%
PatentTitleYear
11,021,719Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo202110,893,666Production of fertile XY female animals by silencing of genes on the Y chromosome202110,894,965Genetic modification of rats202110,793,874Methods and compositions for targeted genetic modifications and methods of use202010,781,453Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locus202010,711,280Methods and compositions for the targeted modification of a mouse ES cell genome202010,457,960Methods and compositions for targeted genetic modification using paired guide RNAs201910,344,299Compositions and methods for modifying cells201910,329,582Genetic modification of rats201910,301,646Nuclease-mediated targeting with large targeting vectors201910,294,494Methods and compositions for modifying a targeted locus201910,208,317Methods and compositions for the targeted modification of a mouse embryonic stem cell genome201910,106,820Methods and compositions for modifying a targeted locus201810,039,269Methods and compositions for generating a mouse201810,023,916Markers of tumor cell response to anti-cancer therapy20189,902,971'Methods for producing a mouse XY embryonic (ES) cell line capable of producing a fertile XY female mouse in an F0 generation'20189,885,058'Production of fertile XY female mice from XY mouse ES cells'20189,834,786Nuclease-mediated targeting with large targeting vectors20179,745,598'miRNA-regulated differentiation-dependent self-deleting cassette'20179,730,434'Methods and compositions for generating a mouse'20179,677,129'Method for detecting the replacement of an endogenous allele with a modified allele by homologous recombination in a mouse ES cell'20179,677,086'Promoter-regulated differentiation-dependent self-deleting cassette'20179,655,351'Production of fertile XY female animals from XY ES cells'20179,554,564'IncRNA-knockout mice'20179,546,384'Methods and compositions for the targeted modification of a mouse genome'20179,414,575'Methods and compositions for generating a mouse'20169,410,163'Promoter-regulated differentiation-dependent self-deleting cassette'20169,398,762'Production of fertile XY female animals from XY ES cells'20169,267,152'MiRNA-regulated differentiation-dependent self-deleting cassette'20169,228,208'Methods and compositions for the targeted modification of a genome'20169,149,026'Production of fertile XY animals from XY ES cells'20159,096,870'miRNA-regulated differentiation-dependent self-deleting cassette'20158,946,504'Promoter-regulated differentiation-dependent self-deleting cassette'20158,946,505'Promoter-regulated differentiation-dependent self-deleting cassette'20158,846,402'Method for genetically modifying isolated non-human mammalian cell by homologous recombination'20148,816,150'Conditioned culture media'20148,759,105'Method for genetically modifying mouse embryonic stem cell by homologous recombination'20148,697,851'MiRNA-regulated differentiation-dependent self-deleting cassette'20148,518,392'Promoter-regulated differentiation-dependent self-deleting cassette'20138,354,389'miRNA-regulated differentiation-dependent self-deleting cassette'20137,659,442'Method for making homozygous genetic modifications'20107,576,259'Method for making genetic modifications'20097,294,754'Method for generating an animal homozygous for a genetic modification'2007Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2007–2021Patents assigned to REGENERON PHARMA (43)· patent assignee history
2007–2021Based in New York, NY, US· patent location history
2013–2017Patents assigned to FRENDEWEY DAVID (6)· patent assignee history
2013–2017Patents assigned to VALENZUELA DAVID M (5)· patent assignee history
2014–2015Patents assigned to AUERBACH WOJTEK (2)· patent assignee history
2014–2017Patents assigned to ECONOMIDES ARIS N (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| REGENERON PHARMA | 43 | 2007–2021 |
| FRENDEWEY DAVIDself | 6 | 2013–2017 |
| VALENZUELA DAVID M | 5 | 2013–2017 |
| AUERBACH WOJTEK | 2 | 2014–2015 |
| ECONOMIDES ARIS N | 2 | 2014–2017 |
Locations
| Location | Patents | Span |
|---|---|---|
| New York, New York, US | 43 | 2007–2021 |